These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 11797767)

  • 21. Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis.
    Guirakhoo F; Zhang ZX; Chambers TJ; Delagrave S; Arroyo J; Barrett AD; Monath TP
    Virology; 1999 May; 257(2):363-72. PubMed ID: 10329547
    [TBL] [Abstract][Full Text] [Related]  

  • 22. West Nile Virus: is a vaccine needed?
    Martina BE; Koraka P; Osterhaus AD
    Curr Opin Investig Drugs; 2010 Feb; 11(2):139-46. PubMed ID: 20112163
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Technologies for the development of West Nile virus vaccines.
    Ulbert S; Magnusson SE
    Future Microbiol; 2014; 9(10):1221-32. PubMed ID: 25405890
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Live measles vaccine expressing the secreted form of the West Nile virus envelope glycoprotein protects against West Nile virus encephalitis.
    Desprès P; Combredet C; Frenkiel MP; Lorin C; Brahic M; Tangy F
    J Infect Dis; 2005 Jan; 191(2):207-14. PubMed ID: 15609230
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mapping and analysis of West Nile virus-specific monoclonal antibodies: prospects for vaccine development.
    Throsby M; Ter Meulen J; Geuijen C; Goudsmit J; de Kruif J
    Expert Rev Vaccines; 2007 Apr; 6(2):183-91. PubMed ID: 17408368
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assurance of neuroattenuation of a live vaccine against West Nile virus: a comprehensive study of neuropathogenesis after infection with chimeric WN/DEN4Δ30 vaccine in comparison to two parental viruses and a surrogate flavivirus reference vaccine.
    Maximova OA; Speicher JM; Skinner JR; Murphy BR; St Claire MC; Ragland DR; Herbert RL; Pare DR; Moore RM; Pletnev AG
    Vaccine; 2014 May; 32(26):3187-97. PubMed ID: 24736001
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A West Nile virus (WNV) recombinant canarypox virus vaccine elicits WNV-specific neutralizing antibodies and cell-mediated immune responses in the horse.
    El Garch H; Minke JM; Rehder J; Richard S; Edlund Toulemonde C; Dinic S; Andreoni C; Audonnet JC; Nordgren R; Juillard V
    Vet Immunol Immunopathol; 2008 Jun; 123(3-4):230-9. PubMed ID: 18372050
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A plant-produced vaccine protects mice against lethal West Nile virus infection without enhancing Zika or dengue virus infectivity.
    Lai H; Paul AM; Sun H; He J; Yang M; Bai F; Chen Q
    Vaccine; 2018 Mar; 36(14):1846-1852. PubMed ID: 29490880
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy, duration, and onset of immunogenicity of a West Nile virus vaccine, live Flavivirus chimera, in horses with a clinical disease challenge model.
    Long MT; Gibbs EP; Mellencamp MW; Bowen RA; Seino KK; Zhang S; Beachboard SE; Humphrey PP
    Equine Vet J; 2007 Nov; 39(6):491-7. PubMed ID: 18065305
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenicity and protective efficacy of recombinant Modified Vaccinia virus Ankara candidate vaccines delivering West Nile virus envelope antigens.
    Volz A; Lim S; Kaserer M; Lülf A; Marr L; Jany S; Deeg CA; Pijlman GP; Koraka P; Osterhaus AD; Martina BE; Sutter G
    Vaccine; 2016 Apr; 34(16):1915-26. PubMed ID: 26939903
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety of an attenuated West Nile virus vaccine, live Flavivirus chimera in horses.
    Long MT; Gibbs EP; Mellencamp MW; Zhang S; Barnett DC; Seino KK; Beachboard SE; Humphrey PP
    Equine Vet J; 2007 Nov; 39(6):486-90. PubMed ID: 18065304
    [TBL] [Abstract][Full Text] [Related]  

  • 32. West Nile virus infection and serologic response among persons previously vaccinated against yellow fever and Japanese encephalitis viruses.
    Johnson BW; Kosoy O; Martin DA; Noga AJ; Russell BJ; Johnson AA; Petersen LR
    Vector Borne Zoonotic Dis; 2005; 5(2):137-45. PubMed ID: 16011430
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A recombinant West Nile virus envelope protein vaccine candidate produced in Spodoptera frugiperda expresSF+ cells.
    Bonafé N; Rininger JA; Chubet RG; Foellmer HG; Fader S; Anderson JF; Bushmich SL; Anthony K; Ledizet M; Fikrig E; Koski RA; Kaplan P
    Vaccine; 2009 Jan; 27(2):213-22. PubMed ID: 18996430
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plant-made vaccines against West Nile virus are potent, safe, and economically feasible.
    Chen Q
    Biotechnol J; 2015 May; 10(5):671-80. PubMed ID: 25676782
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The anamnestic serologic response to vaccination with a canarypox virus-vectored recombinant West Nile virus (WNV) vaccine in horses previously vaccinated with an inactivated WNV vaccine.
    Grosenbaugh DA; Backus CS; Karaca K; Minke JM; Nordgren RM
    Vet Ther; 2004; 5(4):251-7. PubMed ID: 15719324
    [TBL] [Abstract][Full Text] [Related]  

  • 36. West Nile virus vaccines - current situation and future directions.
    Ulbert S
    Hum Vaccin Immunother; 2019; 15(10):2337-2342. PubMed ID: 31116691
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New developments in flavivirus vaccines with special attention to yellow fever.
    Pugachev KV; Guirakhoo F; Monath TP
    Curr Opin Infect Dis; 2005 Oct; 18(5):387-94. PubMed ID: 16148524
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The efficacy of inactivated West Nile vaccine (WN-VAX) in mice and monkeys.
    Muraki Y; Fujita T; Matsuura M; Fuke I; Manabe S; Ishikawa T; Okuno Y; Morita K
    Virol J; 2015 Apr; 12():54. PubMed ID: 25889682
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A recombinant fusion protein consisting of West Nile virus envelope domain III fused in-frame with equine CD40 ligand induces antiviral immune responses in horses.
    Liu SA; Haque M; Stanfield B; Andrews FM; Roy AA; Kousoulas KG
    Vet Microbiol; 2017 Jan; 198():51-58. PubMed ID: 28062007
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections.
    Monath TP; McCarthy K; Bedford P; Johnson CT; Nichols R; Yoksan S; Marchesani R; Knauber M; Wells KH; Arroyo J; Guirakhoo F
    Vaccine; 2002 Jan; 20(7-8):1004-18. PubMed ID: 11803060
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.